BSX

AI Research

Securities Lawsuits Filed → Citi Cuts PT to $94 While 35 Analysts Maintain Strong Buy

Boston Scientific faces multiple securities class action lawsuits launched or expanded by law firms in early 2026, adding legal complexity to an otherwise impressive financial performance and raising stock valuation questions. Citi lowered its price target to $94 from $102 while maintaining a Buy rating, reflecting caution around litigation risk and potential recall-related costs. Despite these headwinds, 35 analysts rate BSX as Strong Buy with an average price target of $103.82, and the company's next earnings report is scheduled for April 29, 2026, which will be key to reassessing the growth trajectory.